Biomarkers in the assessment of diabetic retinopathy progression
https://doi.org/10.21516/2072-0076-2026-19-1-203-209
Abstract
Diabetic retinopathy (DR) is the most common microvascular complication of diabetes mellitus (DM) and the leading cause of acquired blindness in people of working age. Due to the absence of obvious symptoms in the early stages of the disease, the identification of clinical biomarkers can play a crucial role in early diagnosis and in identifying prognostic factors for DR. Major risk factors do not explain the large variability that characterizes the evolution and rate of progression of DR in different individuals. Therefore, the identification of ocular and systemic biomarkers is crucial for facilitating risk stratification in patients with DM; furthermore, reliable biomarkers can also help predict patient response to therapy. Since existing treatments for proliferative DR are mostly applied in advanced stages of the disease, reliable progression criteria are necessary to ensure timely treatment and early and appropriate selection of therapy. This review discusses relevant systemic and local biomarkers of DR.
About the Authors
R. R. Fayzrakhmanov
N.I. Pirogov National Medical and Surgical Center
Russian Federation
Russian Federation
Rinat R. Fayzrakhmanov — Dr. of Med. Sci., director of the ophthalmology center
70, Nizhnyaya Pervomayskaya St., Moscow, 105203
O. A. Pavlovskiy
N.I. Pirogov National Medical and Surgical Center
Russian Federation
Russian Federation
Oleg A. Pavlovskiy — Cand. Med. Sci., ophthalmologist of the ophthalmology center
70, Nizhnyaya Pervomayskaya St., Moscow, 105203
S. N. Saraeva
N.I. Pirogov National Medical and Surgical Center
Russian Federation
Russian Federation
Sofia N. Saraeva — ophthalmologist of the ophthalmology center
70, Nizhnyaya Pervomayskaya St., Moscow, 105203
A. O. Martynov
N.I. Pirogov National Medical and Surgical Center
Russian Federation
Russian Federation
Andrey O. Martynov — ophthalmologist of the ophthalmology center
70, Nizhnyaya Pervomayskaya St., Moscow, 105203
References
1. He X, Cheng R, Benyajati S, Ma JX. PEDF and its roles in physiological and pathological conditions: implication in diabetic and hypoxia-induced angiogenic diseases. Clinical Science. 2015; 128: 805–23. doi:10.1042/CS20130463
2. Qing S, Yuan S, Yun C, et al. Serum miRNA biomarkers serve as a fingerprint for proliferative diabetic retinopathy. Cell Physiol Biochem 2014; 34 (5): 1733–40. doi:10.1159/000366374
3. Sabanayagam C, Banu R, Chee ML, et al. Incidence and progression of diabetic retinopathy: a systematic review. The Lancet Diabetes & Endocrinology. 2019; 7 (2): 140–9. doi:10.1016/S2213-8587(18)30128-1
4. Neroev V.V., Zaitseva O.V., Mikhailova L.A. Diabetic retinopathy prevalence in the Russian Federation according to all-Russia statistics. Russian ophthalmological journal. 2023; 16 (3): 7–11 (In Russ.). doi: 10.21516/2072-0076-2023-16-3-7-11
5. Filippov V.M., Petrachkov D.V., Budzinskaya M.V., Sidamonidze A.L. Modern concepts of pathogenesis of diabetic retinopathy. Vestnik oftal’mologii. 2021; 137 (5–2): 306–13 (In Russ.). https://doi.org/10.17116/oftalma2021137052306
6. Konovalova K.I., Shishkin M.M., Fayzrakhmanov R.R. Comparative analysis of the level of pro-inflammatory cytokines in tear of patients with advanced proliferative diabetic retinopathy and complicated primary cataract. Sovremennye tekhnologii v oftal'mologii. 2022; 1 (41): 61–6 (In Russ.). doi: 10.21516/2072-0076-2021-14-3-14-18
7. Altmann C, Schmidt MHH. The role of microglia in diabetic retinopathy: Inflammation, microvasculature defects and neurodegeneration. Int J Mol Sci. 2018; 19: 110. doi: 10.3390/ijms19010110
8. Wang W, Lo ACY. Diabetic retinopathy: Pathophysiology and treatments. Int J Mol Sci. 2018; 19: 1816. doi: 10.3390/ijms19061816
9. Al-Dwairi R, El-Elimat T, Aleshawi A, et al. Vitreous levels of vascular endothelial growth factor and platelet-derived growth factor in patients with proliferative diabetic retinopathy: A clinical correlation. Biomolecules. 2023; 13: 1630. doi: 10.3390/biom13111630
10. Fayzrakhmanov R.R., Pavlovskiy O.А., Lukinykh M.A. Morphofunctional parameters of diabetic macular edema after vitreoretinal surgery. Otrazhenie. 2024; 1 (17): 46–50 (In Russ.). doi: 10.25276/2686-6986-2024-1-46-50
11. Fayzrakhmanov R.R., Shishkin M.M., Shatalova E.O., Suhanova A.V. Early switch from anti-VEGF therapy to dexamethasone implant in diabetic macular edema. Fyodorov journal of ophthalmic surgery. 2020; 4: 86–92 (In Russ.). doi: 10.25276/0235-4160-2020-4-86-92
12. Kuiper EJ, Hughes JM, Van Geest RJ, et al. Effect of VEGF-A on expression of profibrotic growth factor and extracellular matrix genes in the retina. Invest Ophthalmol Vis Sci. 2007; 48 (9): 4267–76. doi:10.1167/iovs.06-0804
13. Vasan R.S. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation. 2006 May 16; 113 (19): 2335–62. doi: 10.1161/CIRCULATIONAHA.104.482570
14. Konradi A.O. Biomarkers, types and role in personalized medicine. Russian journal for personalized medicine. 2022; 2 (3): 6–16 (In Russ.). doi: 10.18705/2782-3806-2022-2-3-6-16
15. Ahuja S, Saxena S, Akduman L, et al. Serum vascular endothelial growth factor is a biomolecular biomarker of severity of diabetic retinopathy. Int J Retina Vitreous. 2019 Oct 1; 5: 29. doi: 10.1186/s40942-019-0179-6
16. Jenkins AJ, Joglekar MV, Hardikar AA, et al. Biomarkers in diabetic retinopathy. Rev Diabet Stud. 2015; 12: 159–95. doi:10.1900/RDS.2015.12.159
17. Gouliopoulos NS, Kalogeropoulos C, Lavaris A, et al. Association of serum inflammatory markers and diabetic retinopathy: a review of literature. Eur Rev Med Pharmacol Sci. 2018; 22: 7113–28. doi:10.26355/eurrev_201811_16243
18. Whitehead M, Wickremasinghe S, Osborne A, Van Wijngaarden P, Martin KR. Diabetic retinopathy: a complex pathophysiology requiring novel therapeutic strategies. Expert Opin Biol Ther. 2018; 18: 1257–70. doi: 10.1080/14712598.2018.1545836
19. Ting DS, Tan KA, Phua V, et al. Biomarkers of diabetic retinopathy. Curr Diab Rep. 2016; 16 (12): 125. doi: 10.1007/s11892-016-0812-9
20. Marques IP, Madeira MH, Messias AL, et al. Retinopathy phenotypes in type 2 diabetes with different risks for macular edema and proliferative retinopathy. J Clin Med. 2020; 9: 1433. doi:10.3390/jcm9051433
21. Filippov V.M., Petrachkov D.V., Budzinskaya M.V., Matyushchenko A.G. The role of neurodegeneration biomarkers in the management of patients with diabetic retinopathy.Vestnik oftal’mologii. 2021; 137 (5–2): 314–22 (In Russ.). doi: 10.17116/oftalma2021137052314
22. Shah S, Feher M, McGovern A, et al. Diabetic retinopathy in newly diagnosed Type 2 diabetes mellitus: Prevalence and predictors of progression; a national primary network study. Diabetes Res Clin Pract. 2021; 175: 108776. doi: 10.1016/j.diabres.2021.108776
23. Tarasewicz D, Conell C, Gilliam LK. et al. Quantification of risk factors for diabetic retinopathy progression. Acta Diabetol. 2023; 60: 363–9. doi: 10.1007/s00592-022-02007-6
24. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group; Lachin JM, Genuth S, Cleary P, Davis MD, Nathan DM. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000; 342 (6): 381–9. doi: 10.1056/NEJM200002103420603
25. Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: a systematic review. JAMA. 2007; 298 (8): 902–16. doi: 10.1001/jama.298.8.902
26. Lind M, Oden A, Fahlen M, Eliasson B. The shape of the metabolic memory of HbA1c: reanalysing the DCCT with respect to time-dependent effects. Diabetologia. 2010; 53 (6): 1093–8. doi: 10.1007/s00125-010-1706-z
27. Kuo CYJ, Murphy R, Rupenthal ID, Mugisho OO. Correlation between the progression of diabetic retinopathy and inflammasome biomarkers in vitreous and serum - a systematic review. BMC Ophthalmol. 2022; 22 (1): 238. doi: 10.1186/s12886-022-02439-2
28. Pessoa B, Heitor J, Coelho C, et al. Systemic and vitreous biomarkers — new insights in diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2022; 260 (8): 2449–60. doi: 10.1007/s00417-022-05624-7
29. Shaker OG, Abdelaleem OO, Mahmoud RH, et al. Diagnostic and prognostic role of serum MiR-20b, MiR-17-3p, HOTAIR, and MALAT1 in diabetic retinopathy. IUBMB Life. 2019; 71: 310–20. doi: 10.1002/iub.1970
30. Liang Z, Gao KP, Wang YX, et al. RNA sequencing identified specific circulating MiRNA biomarkers for early detection of diabetes retinopathy. Am J Physiol-Endocrinol Metab. 2018; 315: E374-E385. doi: 10.1152/ajpendo.00021.2018
31. Atchison E, Barkmeier A. The role of systemic risk factors in diabetic retinopathy. Curr Ophthalmol Rep. 2016; 4: 84–9. doi: 10.1007/s40135-016- 0098-8
32. Babayeva D.B., Shishkin M.M., Fayzrakhmanov R.R., Konovalova K.I. Vitreopapillary traction syndrome in patients with proliferative diabetic retinopathy. Vestnik oftal’mologii. 2021; 137 (6): 38–44 (In Russ.). doi: 10.17116/oftalma202113706138
33. Loukovaara S, Nurkkala H, Tamene F, et al. Quantitative proteomics analysis of vitreous humor from diabetic retinopathy patients. J Proteome Res. 2015; 14: 5131–43. doi: 10.1021/acs.jproteome.5b00900
34. Rbsam A, Parikh S, Fort PE. Role of inflammation in diabetic retinopathy. Int J Mol Sci. 2018; 19 (4): 942. doi:10.3390/ijms19040942
35. Kwon JW, Oh J. Aqueous humor analyses in patients with diabetic retinopathy who had undergone panretinal photocoagulation. J Diabetes Res. 2022; 2022: 1897344. doi: 10.1155/2022/1897344
36. Stravalaci M, Ferrara M, Pathak V, et al. The long pentraxin ptx3 as a new biomarker and pharmacological target in age-related macular degeneration and diabetic retinopathy. Front Pharmacol. 2022; 12: 811344. doi: 10.3389/fphar.2021.811344
37. Lev I.V., Agarkov N.M. Interleukins in lacrimal fluid and diabetic retinopathy. Medical immunology (Russia). 2022; 24 (4): 793–8 (In Russ.). doi: 10.15789/1563-0625-IIL-2499
38. Ka telan S, Ore kovi I, Bi an F, Ka telan H, Gverovi Antunica A. Inflammatory and angiogenic biomarkers in diabetic retinopathy. Biochem Med (Zagreb). 2020 Oct 15; 30 (3): 030502. doi: 10.11613/BM.2020.030502
39. Sadda SR, Nittala MG, Taweebanjongsin W, et al. Quantitative assessment of the severity of diabetic retinopathy. Am J Ophthalmol. 2020; 218: 342–52. doi: 10.1016/j.ajo.2020.05.021
40. Fleifil S, Azzouz L, Yu G, et al. Quantitative biomarkers of diabetic retinopathy using ultra-widefield fluorescein angiography. Clin Ophthalmol. 2024; 18: 1961–70. doi: 10.2147/OPTH.S462223
41. Fayzrakhmanov R.R., Pavlovsky O.A., Lukinykh M.A., Egorova N.S. Surgical treatment of diabetic macular edema. Russian ophthalmological journal. 2024; 17 (3): 139–44 (In Russ.). doi: 10.21516/2072-0076-2024-17-3-139-144
42. Das R, Spence G, Hogg RE, Stevenson M, Chakravarthy U. Disorganization of inner retina and outer retinal morphology in diabetic macular edema. JAMA Ophthalmol. 2018; 136 (2): 202–8. doi: 10.1001/jamaophthalmol.2017.6256
43. Hui VWK, Szeto SKH, Tang F, et al. Optical coherence tomography classification systems for diabetic macular edema and their associations with visual outcome and treatment responses — An updated review. Asia Pac J Ophthalmol (Phila). 2022; 11 (3): 247–57. doi: 10.1097/APO.0000000000000468
44. Greig EC, Brigell M, Cao F, et al. Macular and peripapillary OCTA metrics predict progression in diabetic retinopathy: A sub-analysis of TIME-2b study data. Am J Ophthalmol. 2020; 219: 66–76. doi: 10.1016/j.ajo.2020.06.009
45. Garg I, Uwakwe C, Le R, et al. Nonperfusion area and other vascular metrics by wider field swept-source OCT angiography as biomarkers of diabetic retinopathy severity. Ophthalmol Sci. 2022; 2 (2): 100144. doi: 10.1016/j.xops.2022.100144
46. Kim K, Kim ES, Yu SY. Prediction of diabetic retinopathy severity using a combination of retinal neurodegeneration and capillary nonperfusion on optical coherence tomography angiography. Retina. 2023; 43 (8): 1291–300. doi: 10.1097/IAE.0000000000003820
47. Neroev V.V., Okhotsimskaya T.D., Fadeeva V.A. An account of retinal microvascular changes in diabetes acquired by OCT-angiography. Russian ophthalmological journal. 2017; 10 (2): 40–5 (In Russ.). doi: 10.21516/2072-0076-2017-10-2-40-45
48. Stulova A.N., Semenova N.S., Zheleznyakova A.V., Akopyan V.S., Lipatov D.V. Time-related OCT-A changes in preclinical retinopathy and their association with systemic factors. Acta biomedica scientifica. 2021; 6 (6–1): 122–7 (In Russ.). doi: 10.29413/ABS.2021-6.6-1.14
49. Dai L, Sheng B, Chen T, et al. A deep learning system for predicting time to progression of diabetic retinopathy. Nat Med. 2024; 30 (2): 584–94. doi: 10.1038/s41591-023-02702-z
50. Neroev V.V., Bragin A.A., Zaytseva O.V. Development of a prototype service for the diagnosis of diabetic retinopathy based on fundus photos using artificial intelligence methods. National health care (Russia). 2021; 2 (2): 64–72 (In Russ.). doi: 10.47093/2713-069X.2021.2.2.64-72
Review
For citations:
Fayzrakhmanov R.R., Pavlovskiy O.A., Saraeva S.N., Martynov A.O. Biomarkers in the assessment of diabetic retinopathy progression. Russian Ophthalmological Journal. 2026;19(1):203-209. (In Russ.) https://doi.org/10.21516/2072-0076-2026-19-1-203-209
Views:
235
JATS XML
Email this article 